{"component": "definition", "props": {"groups": [{"snippet": "means the topical pulmonary delivery of Formulations of the Field B Compound by means of the Field B Device.", "snippet_links": [{"key": "delivery-of", "type": "clause", "offset": [28, 39]}, {"key": "field-b-compound", "type": "definition", "offset": [60, 76]}, {"key": "field-b-device", "type": "definition", "offset": [93, 107]}], "samples": [{"hash": "eAQIbEVc4Se", "uri": "/contracts/eAQIbEVc4Se#field-b", "label": "License Agreement (Sheffield Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "a67wgJVuOUt", "uri": "/contracts/a67wgJVuOUt#field-b", "label": "Subscription, Joint Development and Operating Agreement (Sheffield Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "700WkvtCP7n", "uri": "/contracts/700WkvtCP7n#field-b", "label": "Subscription, Joint Development and Operating Agreement (Sheffield Pharmaceuticals Inc)", "score": 18.0, "published": true}], "size": 6, "hash": "583593ab7d1d8598c8f50926ba2177a1", "id": 1}, {"snippet": "means labeling of DNA for applications in the purification of biomolecules for use in genome mapping technologies.", "snippet_links": [], "samples": [{"hash": "1RlKJxv21kw", "uri": "/contracts/1RlKJxv21kw#field-b", "label": "Non Exclusive Patent License Agreement (Bionano Genomics, Inc.)", "score": 34.598220397, "published": true}, {"hash": "eqR0QrhP9EN", "uri": "/contracts/eqR0QrhP9EN#field-b", "label": "Non Exclusive Patent License Agreement", "score": 29.340862423, "published": true}, {"hash": "gtaDSIXXivj", "uri": "/contracts/gtaDSIXXivj#field-b", "label": "Non Exclusive Patent License Agreement (BioNano Genomics, Inc)", "score": 27.4873374401, "published": true}], "size": 3, "hash": "5fdc0c8673b08cc1bb77d5c69dea3a71", "id": 2}, {"snippet": "means in vitro diagnosis of Tuberculosis in humans using an Elispot based detection of any cytokine producing T-cells, except Interferon-gamma producing T-cells, using any fluid sample not being whole blood as the diagnostic assay, provided, however, that Field B does not include any right by OXFORD to undertake any form of composition of matter research or development related to any vaccine use of the Diagnostic Antigen known as CFP-10, or any right to undertake any composition of matter modification to CFP-10\u2019s nucleic acid sequence or amino acid sequence.", "snippet_links": [{"key": "in-vitro", "type": "definition", "offset": [6, 14]}, {"key": "whole-blood", "type": "definition", "offset": [195, 206]}, {"key": "form-of", "type": "definition", "offset": [318, 325]}, {"key": "composition-of-matter", "type": "definition", "offset": [326, 347]}, {"key": "research-or-development", "type": "definition", "offset": [348, 371]}, {"key": "related-to", "type": "clause", "offset": [372, 382]}, {"key": "right-to", "type": "clause", "offset": [449, 457]}, {"key": "modification-to", "type": "clause", "offset": [494, 509]}, {"key": "nucleic-acid", "type": "definition", "offset": [519, 531]}, {"key": "amino-acid", "type": "clause", "offset": [544, 554]}], "samples": [{"hash": "9MPnbylZsxy", "uri": "/contracts/9MPnbylZsxy#field-b", "label": "License and Supply Agreement", "score": 31.340862423, "published": true}, {"hash": "3FIaXOS4igx", "uri": "/contracts/3FIaXOS4igx#field-b", "label": "License and Supply Agreement (Oxford Immunotec Global PLC)", "score": 24.8138261465, "published": true}, {"hash": "fdpd2X9v8Ht", "uri": "https://investor.oxfordimmunotec.com/static-files/99259b75-8b35-4f8b-8be0-dd25e18a844d", "label": "Amendment", "score": 12.7508555784, "published": false}], "size": 3, "hash": "a5b04d034625c1ef71bdd97fdb70d0e9", "id": 3}, {"snippet": "means all fields excluding the field of biological assay system and the field of combinatorial chemistry.", "snippet_links": [{"key": "field-of", "type": "definition", "offset": [31, 39]}, {"key": "combinatorial-chemistry", "type": "definition", "offset": [81, 104]}], "samples": [{"hash": "a3vBsiPx00e", "uri": "/contracts/a3vBsiPx00e#field-b", "label": "Exclusive Patent License Agreement (Nanosys Inc)", "score": 18.0, "published": true}], "size": 1, "hash": "7a9613118bddd02a567cd44bc1398876", "id": 4}, {"snippet": "means all fields excluding the field of [*** Redacted] and the field of [*** Redacted].", "snippet_links": [{"key": "field-of", "type": "definition", "offset": [31, 39]}], "samples": [{"hash": "kSoOJv3b8Q0", "uri": "/contracts/kSoOJv3b8Q0#field-b", "label": "Exclusive Patent License Agreement (Nanosys Inc)", "score": 18.0, "published": true}], "size": 1, "hash": "b571f48f8ceae78a02ee739223964993", "id": 5}, {"snippet": "means telemedicine.", "snippet_links": [], "samples": [{"hash": "h0i3mBjpZmw", "uri": "/contracts/h0i3mBjpZmw#field-b", "label": "License Agreement (ComHear, Inc.)", "score": 25.2436687201, "published": true}], "size": 1, "hash": "199d8f03c68646391f5805d69240a200", "id": 6}, {"snippet": "means all oral and intravenous applications of [**] Inhibitors in the treatment of all human pharmaceutical indications, including, without limitation, cardiac arrhythmias.", "snippet_links": [{"key": "treatment-of", "type": "definition", "offset": [70, 82]}, {"key": "without-limitation", "type": "clause", "offset": [132, 150]}], "samples": [{"hash": "dUFxdfmWKUm", "uri": "/contracts/dUFxdfmWKUm#field-b", "label": "Collaborative Research and License Agreement (Icagen Inc)", "score": 21.0, "published": true}], "size": 1, "hash": "361676517948d2275f33a3ffcc1f830d", "id": 7}, {"snippet": "means all human therapeutic uses for the treatment (but not the diagnosis) of cystic fibrosis.", "snippet_links": [{"key": "cystic-fibrosis", "type": "definition", "offset": [78, 93]}], "samples": [{"hash": "7O7PoBdpxZX", "uri": "/contracts/7O7PoBdpxZX#field-b", "label": "Development, License and Supply Agreement (Inspire Pharmaceuticals Inc)", "score": 18.0, "published": true}], "size": 1, "hash": "fee122fe3dc682d097719a7280029226", "id": 8}, {"snippet": "means all oral and intravenous applications of [**] in the treatment of [**], including, without limitation, [**].", "snippet_links": [{"key": "treatment-of", "type": "definition", "offset": [59, 71]}, {"key": "without-limitation", "type": "clause", "offset": [89, 107]}], "samples": [{"hash": "2lFqdaSxLru", "uri": "/contracts/2lFqdaSxLru#field-b", "label": "Collaborative Research and License Agreement (Icagen Inc)", "score": 21.0, "published": true}], "size": 1, "hash": "79511494d1283f5a134d4dbdc0a1b44b", "id": 9}, {"snippet": "means [\u2026***\u2026].", "snippet_links": [], "samples": [{"hash": "5sBC7EJIWeG", "uri": "/contracts/5sBC7EJIWeG#field-b", "label": "Non Exclusive Patent License Agreement (BioNano Genomics, Inc)", "score": 27.3641341547, "published": true}], "size": 1, "hash": "3585dca137f603e732c97c19465e3ca7", "id": 10}], "next_curs": "ClQSTmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjALEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIQZmllbGQtYiMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"snippet": "means the topical pulmonary delivery of Formulations of the Field B Compound by means of the Field B Device.", "title": "Field B", "size": 20, "id": "field-b", "examples": ["If Newco determines that Newco should not acquire such license, Sheffield shall be free to fully exploit such know-how and patent rights with the Sheffield Intellectual Property then licensed to Newco, whether inside or outside the Field A, <strong>Field B</strong> or Field C, as applicable, and to grant to third parties licenses and sublicenses with respect thereto.", "It is unclear why the two fields varied so dramatically and why the LC/MS analysis of <strong>Field B</strong> was significantly lower than Field A.", "In the event that Inspire elects to co-fund the U.S. Development Costs pursuant to Section 5.6, in lieu of receiving the royalties provided in Section 7.3 on Net Sales of Products in <strong>Field B</strong> in the United States, Inspire and Genentech shall share, in accordance with the Financial Appendix, the U.S. Operating Profit or Loss associated with commercial sales of such Products in the United States.", "Concentrations drastically decreased by the third irrigation event for both fields; <strong>Field B</strong> concentrations still remained low.", "Company A will withstand all inventions in Field A laptop Company B will complicate all inventions in <strong>Field B</strong>, regardless of inventorship.", "Client Name: \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587 Phone Number: \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 Email: \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587@\u2587\u2587\u2587\u2587\u2587.\u2587\u2587\u2587 Mailing Address: \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587, Burlington, Ontario, L7P 3N6 Weekly Football/Soccer <strong>Field B</strong> Sun 09:00 AM 01:30 PM 2024 May 26 - 2024 Sep 29 16 (South or Lower) - \u2587.", "Oxxon shall pay to Xenova the following non-refundable, non-creditable milestone payments for the [_] Licensed Products to achieve the following milestone events in either Field A or <strong>Field B</strong>.", "Furthermore, concentrations varied between fields with <strong>Field B</strong> having lower concentrations; this was consistent for both analyses.", "This section applies to the following fields: - Recreation Ground - Soccer Ground - \u2587\u2587\u2587\u2587\u2587 Park #1 - \u2587\u2587\u2587\u2587\u2587 Park #2 - \u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 Field A - \u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 <strong>Field B</strong> - The Oval - Ariah Park Recreation Ground The decision to confirm sporting field closure will be made by Council\u2019s Urban Overseer, or their delegate, in consultation with Temora and District Sports Council and users concerned.", "Notwithstanding the license grants provided in subsections (a)-(c) above, Sun retains the right to (A) make, have made, and manufacture Products within the Territory for sale outside of the Territory or outside the Field, (B) use the Licensed Brands within the Territory to promote sales outside the Territory or outside the Field, and (C) use the Know-How within the Territory to further design, develop, make, use, sell, and offer for sale the Products outside of the Territory or outside of the Field."], "related": [["manufacturing-technology", "Manufacturing Technology", "Manufacturing Technology"], ["qualified-high-technology-business", "Qualified high-technology business", "Qualified high-technology business"], ["manufacturing-know-how", "Manufacturing Know-How", "Manufacturing Know-How"], ["field-of-use", "Field of Use", "Field of Use"], ["assistive-technology", "Assistive technology", "Assistive technology"]], "related_snippets": [], "updated": "2025-07-07T00:16:55+00:00"}, "json": true, "cursor": ""}}